VRCA
Verrica Pharmaceuticals Inc

2,342
Mkt Cap
$78.85M
Volume
154,057.00
52W High
$9.82
52W Low
$3.28
PE Ratio
-2.41
VRCA Fundamentals
Price
$8.31
Prev Close
$8.30
Open
$8.22
50D MA
$5.80
Beta
0.59
Avg. Volume
313,232.11
EPS (Annual)
-$14.78
P/B
-4.62
Rev/Employee
$106,563.38
Loading...
Loading...
News
all
press releases
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2%
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 380,561...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Armistice Capital LLC Increases Stock Holdings in Verrica Pharmaceuticals Inc. $VRCA
Armistice Capital LLC boosted its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 3.7% in the second quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·20d ago
News Placeholder
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Purchases 94,311 Shares
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) CEO Jayson Rieger acquired 94,311 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The shares were...
MarketBeat·1mo ago
News Placeholder
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) breached their fiduciary duties to shareholders...
Business Wire·2mo ago
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +102.86% and +154.04%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Zacks·8mo ago
News Placeholder
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
Zacks·8mo ago
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
chainwire·8mo ago
<
...
1
>

Latest VRCA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.